Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and rifamycins

levofloxacin has been researched along with rifamycins in 16 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(rifamycins)		Trials
(rifamycins)		Recent Studies (post-2010) (rifamycins)
4,3465812,2092,351203626

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (31.25)18.2507
2000's7 (43.75)29.6817
2010's4 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dhople, AM; Ibanez, MA1
Akaki, T; Sato, K; Tomioka, H2
Akaki, T; Kawahara, S; Sato, K; Shimizu, T; Tomioka, H1
Akaki, T; Ogasawara, K; Sato, K; Tomioka, H1
Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H1
Akaki, T; Kawahara, S; Sato, K; Tomioka, H1
Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H1
Hammerschlag, MR; Kutlin, A; Reznik, T; Roblin, PM1
Cammarota, G; Candelli, M; Cazzato, A; Finizio, R; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lauritano, EC; Nista, EC; Ojetti, V; Santoro, M; Zocco, MA1
Murphy, CK; Osburne, MS; Rothstein, DM1
Landmann, R; Murphy, CK; Rothstein, DM; Trampuz, A; Widmer, AF; Zimmerli, W1
Choi, KH; Chung, WC; Jung, SH; Kang, BK; Kim, EJ; Lee, KM; Oak, JH; Paik, CN1
Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ1
Ang, TL; Song, M1
Tribble, DR1

Reviews

1 review(s) available for levofloxacin and rifamycins

ArticleYear
Second and third line treatment options for Helicobacter pylori eradication.
    World journal of gastroenterology, 2014, Feb-14, Volume: 20, Issue:6

    Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors

2014

Trials

2 trial(s) available for levofloxacin and rifamycins

ArticleYear
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study.
    Digestive diseases (Basel, Switzerland), 2006, Volume: 24, Issue:1-2

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pilot Projects; Rifamycins; Rifaximin; Treatment Outcome

2006
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
    Journal of Korean medical science, 2011, Volume: 26, Issue:6

    Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Peptic Ulcer; Prospective Studies; Rifamycins; Rifaximin

2011

Other Studies

13 other study(ies) available for levofloxacin and rifamycins

ArticleYear
In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:9

    Topics: Adenosine Triphosphate; Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Synergism; Drug Therapy, Combination; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium leprae; Ofloxacin; Rifamycins; Thymidine

1995
[Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages].
    Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:7

    Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Clarithromycin; Culture Media; Humans; Levofloxacin; Mycobacterium avium Complex; Ofloxacin; Rifamycins

1997
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis

1997
Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
    The Journal of antimicrobial chemotherapy, 1998, Volume: 41, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Female; Levofloxacin; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium avium; Ofloxacin; Phagocytosis; Rifamycins; Tuberculosis

1998
[MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Kekkaku : [Tuberculosis], 1999, Volume: 74, Issue:7

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins

1999
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:2

    Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins

2000
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    International journal of antimicrobial agents, 2000, Volume: 16, Issue:1

    Topics: Anti-Bacterial Agents; Cell Line; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins; Tuberculosis

2000
Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Rifamycins

2002
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rifamycins

2003
Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
    The Journal of antibiotics, 2006, Volume: 59, Issue:5

    Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mupirocin; Ofloxacin; Oxazolidinones; Rifamycins; Staphylococcus aureus

2006
Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Foreign-Body Reaction; Guinea Pigs; Injections, Intraperitoneal; Levofloxacin; Male; Microbial Sensitivity Tests; Molecular Structure; Ofloxacin; Rifampin; Rifamycins; Staphylococcal Infections; Staphylococcus aureus; Time Factors

2007
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7

    Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin

2012
Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.
    Military medicine, 2017, Volume: 182, Issue:S2

    Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Developing Countries; Diarrhea; Dysentery; Humans; Levofloxacin; Military Personnel; Rifamycins; Rifaximin

2017